It has received FDA EUA for treatment of mild to moderate COVID-19 in nonhospitalized adults ≥ 18 years of age who have positive results of direct SARS-CoV-2 viral testing and who are at high risk for progression to severe disease, including hospitalization or death, and for whom alternative COVID-19 treatment options authorized by the FDA are not accessible or clinically appropriate.